Pregnancy and breastfeeding study for women with Fabry disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study follows pregnant and breastfeeding women with Fabry disease (and their infants) to better understand what happens during pregnancy and early life. You may or may not be taking migalastat, and the goal is to gather real-world information that could help future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman with Fabry disease who is currently pregnant and/or breastfeeding
- You (or, if applicable, a guardian) can give informed consent (and assent when needed)
- You can share your healthcare provider’s contact information
- There are no listed study exclusions for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with Fabry disease who took the medicine Elfabrio during pregnancy or breastfeeding to see if it is safe for them and their babies. It helps doctors learn more about how this treatment affects mothers and infants.
This trial tests if the oral drug migalastat is safe and works for children aged 2 to under 12 with a specific type of Fabry disease. It may be an option if your child has not been on enzyme therapy recently and has a compatible gene variant.
This study collects health information from people with Fabry disease and specifically from pregnant people with Fabry disease. It helps researchers better understand the condition and how pregnancy affects health, using information you already experience in routine care.
This study looks at how well available Fabry disease treatments (like migalastat or ERT) work over time in real life. It may help doctors understand who benefits most from these medicines.
This study tests a new gene therapy for children aged 7 to 17 with Fabry disease. The treatment aims to fix the faulty gene that causes the condition, which may help reduce symptoms and prevent organ damage.
This study observes how well the medication pegunigalsidase alfa works over a long period in people with Fabry disease. It helps doctors learn more about managing the condition in everyday life.
Hear when a new Fabry Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.